id,sequence,label,elisa_flags,source
abituzumab,ASFLGRGAMDY,0.0,0,jain2017_pnas
abrilumab,ATGSSSSWFDP,0.0,0,jain2017_pnas
adalimumab,AKVSYLSTASSLDY,0.0,0,jain2017_pnas
alemtuzumab,AREGHTAAPFDY,0.0,0,jain2017_pnas
alirocumab,AKDSNWGNFDL,0.0,0,jain2017_pnas
anifrolumab,ARHDIEGFDY,0.0,0,jain2017_pnas
atezolizumab,ARRHWPGGFDY,0.0,0,jain2017_pnas
bapineuzumab,VRYDHYSGSSDY,0.0,0,jain2017_pnas
basiliximab,SRDYGYYFDF,0.0,0,jain2017_pnas
bavituximab,VKGGYYGHWYFDV,0.0,0,jain2017_pnas
belimumab,ARSRDLLLFPHHALSP,1.0,6,jain2017_pnas
benralizumab,GREGIRYYGLLGDY,0.0,0,jain2017_pnas
bevacizumab,AKYPHYYGSSHWYFDV,0.0,0,jain2017_pnas
bimagrumab,ARGGWFDY,0.0,0,jain2017_pnas
blosozumab,ATGDTTYKFDF,1.0,6,jain2017_pnas
bococizumab,ARERPLYASDL,1.0,6,jain2017_pnas
brentuximab,ANYGNYWFAY,,3,jain2017_pnas
briakinumab,KTHGSHDN,1.0,4,jain2017_pnas
brodalumab,ARRQLYFDY,,1,jain2017_pnas
canakinumab,ARDLRTGPFDY,0.0,0,jain2017_pnas
carlumab,ARYDGIYGELDF,1.0,4,jain2017_pnas
certolizumab,ARGYRSYAMDY,0.0,0,jain2017_pnas
cetuximab,ARALTYYDYEFAY,0.0,0,jain2017_pnas
cixutumumab,ARAPLRFLEWSTQDHYYYYYMDV,1.0,6,jain2017_pnas
clazakizumab,ARDDSSDWDAKFNL,0.0,0,jain2017_pnas
codrituzumab,TRFYSYTY,1.0,6,jain2017_pnas
crenezumab,ASGDY,0.0,0,jain2017_pnas
dacetuzumab,AREGIYW,0.0,0,jain2017_pnas
daclizumab,ARGGGVFDY,,1,jain2017_pnas
dalotuzumab,ARYGRVFFDY,1.0,5,jain2017_pnas
daratumumab,AKDKILWFGEPVFDY,0.0,0,jain2017_pnas
denosumab,AKDPGTTVIMSWFDP,1.0,5,jain2017_pnas
dinutuximab,VSGMEY,0.0,0,jain2017_pnas
drozitumab,AKILGAGRGWYFDY,0.0,0,jain2017_pnas
duligotuzumab,ARESRVSFEAAMDY,1.0,6,jain2017_pnas
dupilumab,AKDRLSITIRPRYYGLDV,1.0,5,jain2017_pnas
eculizumab,ARYFFGSSPNWYFDV,0.0,0,jain2017_pnas
efalizumab,ARGIYFYGTTYFDY,0.0,0,jain2017_pnas
eldelumab,AREGDGSGIYYYYGMDV,0.0,0,jain2017_pnas
elotuzumab,ARPDGNYWYFDV,0.0,0,jain2017_pnas
emibetuzumab,ARANWLDY,1.0,6,jain2017_pnas
enokizumab,ARADYYGSDYVKFDY,0.0,0,jain2017_pnas
epratuzumab,ARRDITTFY,,1,jain2017_pnas
etrolizumab,ARTGSSGYFDF,,2,jain2017_pnas
evolocumab,ARGYGMDV,,2,jain2017_pnas
farletuzumab,ARHGDDPAWFAY,0.0,0,jain2017_pnas
fasinumab,STIFGVVTNFDN,0.0,0,jain2017_pnas
fezakinumab,AREPEKFDSDDSDV,0.0,0,jain2017_pnas
ficlatuzumab,ARNYVGSIFDY,0.0,0,jain2017_pnas
figitumumab,AKDLGWSDSYYYYYGMDV,,3,jain2017_pnas
fletikumab,AREPLWFGESSPHDYYGMDV,0.0,0,jain2017_pnas
foralumab,ARQMGYWHFDL,,2,jain2017_pnas
fresolimumab,ASTLGLVLDAMDY,0.0,0,jain2017_pnas
fulranumab,ARVYSSGWHVSDYFDY,,1,jain2017_pnas
galiximab,VRDRLFSVVGMVYNNWFDV,0.0,0,jain2017_pnas
ganitumab,ARWTGRTDAFDI,0.0,0,jain2017_pnas
gantenerumab,ARGKGNTHKPYGYVRYFDV,1.0,6,jain2017_pnas
gemtuzumab,VNGNPWLAY,0.0,0,jain2017_pnas
gevokizumab,ARNRYDPPWFVD,0.0,0,jain2017_pnas
girentuximab,ARHRSGYFSMDY,0.0,0,jain2017_pnas
glembatumumab,ARGYNWNYFDY,0.0,0,jain2017_pnas
golimumab,ARDRGIAAGGNYYYYGMDV,,1,jain2017_pnas
guselkumab,ARWYYKPFDV,,1,jain2017_pnas
ibalizumab,AREKDNYATGAWFAY,0.0,0,jain2017_pnas
imgatuzumab,ARLSPGGYYVMDA,1.0,5,jain2017_pnas
infliximab,SRNYYGSTYDY,0.0,0,jain2017_pnas
inotuzumab,TREGYGNYGAWFAY,,3,jain2017_pnas
ipilimumab,ARTGWLGPFDY,0.0,0,jain2017_pnas
ixekizumab,ARYDYFTGTGVY,1.0,6,jain2017_pnas
lampalizumab,EREGGVNN,0.0,0,jain2017_pnas
lebrikizumab,AGDGYYPYAMDN,0.0,0,jain2017_pnas
lenzilumab,VRRQRFPYYFDY,1.0,6,jain2017_pnas
lintuzumab,ARGRPAMDY,0.0,0,jain2017_pnas
lirilumab,ARIPSGSYYYDYDMDV,0.0,0,jain2017_pnas
lumiliximab,ASLTTGSDS,0.0,0,jain2017_pnas
matuzumab,ASRDYDYDGRYFDY,0.0,0,jain2017_pnas
mavrilimumab,AIVGSFSPLTLGL,0.0,0,jain2017_pnas
mepolizumab,ARDPPSSLLRLDY,0.0,0,jain2017_pnas
mogamulizumab,GRHSDGNFAFGY,0.0,0,jain2017_pnas
motavizumab,ARDMIFNFYFDV,,1,jain2017_pnas
muromonab,ARYYDDHYCLDY,0.0,0,jain2017_pnas
natalizumab,AREGYYGNYGVYAMDY,0.0,0,jain2017_pnas
necitumumab,ARVSIFGVGTFDY,0.0,0,jain2017_pnas
nimotuzumab,TRQGLWFDSDGRGFDF,0.0,0,jain2017_pnas
nivolumab,ATNDDY,0.0,0,jain2017_pnas
obinutuzumab,ARNVFDGYWLVY,0.0,0,jain2017_pnas
ocrelizumab,ARVVYYSNSYWYFDV,0.0,0,jain2017_pnas
ofatumumab,AKDIQYGNYYYGMDV,0.0,0,jain2017_pnas
olaratumab,ARQSTYYYGSGNYYGWFDR,0.0,0,jain2017_pnas
olokizumab,ARESYYGFTSY,0.0,0,jain2017_pnas
omalizumab,ARGSHYFGHWHFAV,0.0,0,jain2017_pnas
onartuzumab,ATYRSYVTPLDY,0.0,0,jain2017_pnas
otelixizumab,AKFRQYSGGFDY,0.0,0,jain2017_pnas
otlertuzumab,ARSVGPFDS,0.0,0,jain2017_pnas
ozanezumab,ELMQGY,,3,jain2017_pnas
palivizumab,ARSMITNWYFDV,0.0,0,jain2017_pnas
panitumumab,VRDRVTGAFDI,0.0,0,jain2017_pnas
panobacumab,ARDRYYGPEM,0.0,0,jain2017_pnas
parsatuzumab,AREGVYHDYDDYAMDY,1.0,6,jain2017_pnas
patritumab,ARDKWTWYFDL,1.0,4,jain2017_pnas
pembrolizumab,ARRDYRFDMGFDY,0.0,0,jain2017_pnas
pertuzumab,ARNLGPSFYFD,0.0,0,jain2017_pnas
pinatuzumab,ARDGSSWDWYFDV,0.0,0,jain2017_pnas
polatuzumab,TRRVPIRLDY,0.0,0,jain2017_pnas
ponezumab,ASLYSLPVY,1.0,4,jain2017_pnas
radretumab,AKPFPYFDY,0.0,0,jain2017_pnas
ramucirumab,ARVTDAFDI,0.0,0,jain2017_pnas
ranibizumab,AKYPYYYGTSHWYFDV,,1,jain2017_pnas
reslizumab,AREYYGYFDY,0.0,0,jain2017_pnas
rilotumumab,ARGGYDFWSGYFDY,0.0,0,jain2017_pnas
rituximab,ARSTYYGGDWYFNV,0.0,0,jain2017_pnas
robatumumab,ARLGNFYYGMDV,1.0,4,jain2017_pnas
romosozumab,ARLGYDDIYDDWYFDV,0.0,0,jain2017_pnas
sarilumab,AKGRDSFDI,0.0,0,jain2017_pnas
secukinumab,VRDYYDILTDYYIHYWYFDL,0.0,0,jain2017_pnas
seribantumab,TRGLKMATIFDY,0.0,0,jain2017_pnas
sifalimumab,ARDPIAAGY,,3,jain2017_pnas
siltuximab,ARGLWGYYALDY,0.0,0,jain2017_pnas
simtuzumab,ARNWMNFDY,1.0,6,jain2017_pnas
sirukumab,ARQLWGYYALDI,1.0,5,jain2017_pnas
tabalumab,ARGYYDILTGYYYYFDY,0.0,0,jain2017_pnas
tanezumab,ARGGYWYATSYYFDY,,1,jain2017_pnas
teplizumab,ARYYDDHYCLDY,,2,jain2017_pnas
tigatuzumab,ARRGDSMITTDY,0.0,0,jain2017_pnas
tildrakizumab,ARGGGGFAY,0.0,0,jain2017_pnas
tocilizumab,ARSLARTTAMDY,0.0,0,jain2017_pnas
tovetumab,AREGRIAARGMDV,0.0,0,jain2017_pnas
tralokinumab,ARDSSSSWARWFFDL,0.0,0,jain2017_pnas
trastuzumab,SRWGGDGFYAMDY,0.0,0,jain2017_pnas
tremelimumab,ARDPRGATLYYYYYGMDV,0.0,0,jain2017_pnas
urelumab,ARDYGPGNYDWYFDL,0.0,0,jain2017_pnas
ustekinumab,ARRRPGQGYFDF,,3,jain2017_pnas
vedolizumab,ARGGYDGWDYAIDY,0.0,0,jain2017_pnas
veltuzumab,ARSTYYGGDWYFDV,0.0,0,jain2017_pnas
visilizumab,ARSAYYDYDGFAY,,3,jain2017_pnas
zalutumumab,ARDGITMVRGVMKDYFDY,,1,jain2017_pnas
zanolimumab,ARVINWFDP,0.0,0,jain2017_pnas
